A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 3103 participants.

Also called NCT07000123

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 3,103 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07000123
  • EudraCT 2025-520521-21
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Brazil, Bulgaria, Canada, Chile, Czechia, Germany, Hungary, India, Japan, Malaysia, Poland, Slovakia, South Korea, Spain, Taiwan, Türkiye, Ukraine, United Kingdom, Vietnam (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT07000123. Randomized; triple masking; primary purpose treatment. Start 2025-05-28 (actual); primary completion 2027-01-11 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event
Acronym
AZURE-LDL
Condition
Cardiovascular Disease
Intervention (Drug)
AZD0780
Intervention (Drug)
Placebo
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct07000123
Content hash
f3e40100301be87fa69bc53ee7ed5c4965162a0fa52326634c614fbc09b91f05